Category Archives: Strategy

Baxter Splits Biopharm and Medical Products into Two Businesses

Baxter International plans to create two separate, independent global healthcare companies, with one focused on biopharmaceuticals and the other on medical products.
Also posted in Biotech | Tagged , , | Leave a comment

Allergy Shots in a Pill?

Allergy season’s dank fecundity might be welcomed in many parts of America this year. Anything that’s warmer. But the worst allergy sufferers might soon be headed back to the doctor’s office for another round of allergy shots. Or perhaps not. ALK-Abelló, a Denmark-based specialty pharmaceuticals company focused solely on allergy immunotherapy products, expects FDA to […]
Also posted in Biotech, Europe, FDA, R&D, Regulatory, Technology | Tagged , , , , , , , , , | Leave a comment

FDA, Sponsors Seek Study Endpoints Earlier in Development

As payers demand more evidence documenting medical product value, biopharma companies are responding by moving sooner to decide key clinical outcomes to measure. While clinical trials still have to document product safety, efficacy and quality, sponsors also look to demonstrate suitability for formulary placement and reimbursement. Food and Drug Administration officials support these strategies to […]
Also posted in FDA, Marketing, R&D, Regulatory | Tagged , , , , | 1 Comment

Outlook “Gloomy” for TB Investment

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
Also posted in Emerging Markets, Global | Tagged , , , , , | Leave a comment

“The Secret of Successful Drug Launches”

We love being told secrets especially about something so few know anything about, like how to launch a drug successfully given two-thirds don’t meet expectations. And those new drugs once launched fail to meet prelaunch consensus sales expectations for their first year on the market, and those that fall short typically continue to under-deliver for […]
Also posted in Marketing | Tagged , , | 1 Comment
  • Categories

  • Meta